2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5239 Identification of chromosomal lesion-specific drivers of leukemia cell states in TP53-mutant AML by single cell RNA-sequencing

Varsha Singh, PhD, Meredith Elise Arterburn2, Michael Bowman, PhD3, Dana Bellissimo, MD, PhD4, Shreeya Gounder5, Alyssa M Klein, MD, PhD6, Matei Ionita, PhD7, Michelle L Mckeague, PhD8, Pamela J. Sung, MD PhD9, Martin Carroll, MD10, Sarah Skuli, MD, PhD11, Robert L Bowman, PhD12
1 University of Pennsylvania, Phildelphia, Pennsylvania, United States, University of Pennsylvania, Phildelphia, Pennsylvania, United States
2 University of Pennsylvania, Phildelphia, Pennsylvania, United States
3 University of Pennsylvania, Phildelphia, Pennsylvania, United States
4 University of Pennsylvania, Phildelphia, Pennsylvania, United States
5 University of Pennsylvania, Phildelphia, Pennsylvania, United States
6 University of Pennsylvania, Phildelphia, Pennsylvania, United States
7 University of Pennsylvania, Phildelphia, Pennsylvania, United States
8 University of Pennsylvania, Phildelphia, Pennsylvania, United States
9 Roswell park, Buffalo, New York, United States
10 University of Pennsylvania, Phildelphia, Pennsylvania, United States
11 University of Cincinnati, Cincinnati, Ohio, United States
12 University of Pennsylvania, Phildelphia, Pennsylvania, United States

TP53-mutant (MT) acute myeloid leukemia (AML) is characterized by complex karyotype and uniformly poor clinical outcomes. TP53-MT AML often lacks common cooperating mutations (FLT3, IDH1/2, or NPM1), nominating recurrent copy number variations (CNV) as drivers of leukemia cell identity. Given extensive inter and intra patient heterogeneity, bulk genomic studies cannot resolve how individual CNVs shape leukemia cell states and transcriptional programs. Uncovering these cellular consequences will identify collateral therapeutic vulnerabilities that can be co-opted to target TP53-MT AML.

To define the cellular consequences of CNVs we performed single cell-RNA sequencing (QuantumScale) on bone marrow aspirates at diagnosis from 67 AML patients (40 TP53-MT, 27 TP53-wildtype (WT); median age 66y, 69% de novo). Complex karyotype was identified in 38 of 40 TP53-MT patients and dominated by 4 recurrent chromosomal lesions: del5q, del7, trisomy 8 (tri8) and del17, occurring alone or in combination. TP53 patients differed significantly in median overall survival, ranging from 1.1m for del7 to 34m for normal karyotype (NK) (log-rank p=0.007). We profiled 238,336 cells with a median 3548 cells/sample and 2686 genes/cell. Cell types were called with reference maps (PMID 40294241): and were found across stem/progenitor cells to differentiated lineages. Single-cell CNVs were inferred using a 2-standard deviation cutoff from reference cells and validated against 17 TP53-WT NK controls using inferCNV. Cells with single and compound CNVs were tested using mixed-effects models with sample source as a random effect. Transcriptional programs were characterized by GSEA, transcription factor (TF) activity (decoupleR), and differential expression (Wilcoxon).

 We first determined how CNVs altered leukemic cell differentiation. Compared to TP53-WT, TP53-MT AML showed increased erythroid progenitors (13.8% vs 2.8%, p=0.005) and reduced monocytic cells (29.6% vs 44.9%, p=0.049). Within TP53-MT, del5q cases showed increased erythroid differentiation compared with non-del5q cases (13.9% vs 1.8%, p=0.026), while tri8 cases showed reduced monocytic differentiation (7.2% vs 31.1%, p=0.011); combined del5q:tri8 antagonized these biases with blunted erythroid enrichment (p=0.131 vs del5q) and monocytic depletion (p=0.32 vs tri8).

 We next sought to determine the clonal heterogeneity of CNVs in each individual TP53-MT samples. Tri8 clones comprised 21–74% of leukemic cells across patients, while del5q clone fractions ranged from 32–83%. Del17 was restricted to a secondary subclone, whereas del5q or del7 constituted the dominant clone. Moreover, cells harboring multiple CNVs were detected in most TP53-MT patients (median 22.2% of blasts/patient), regardless of their clinical cytogenetics.

 Given that most TP53-MT cells possess multiple chromosomal abnormalities, we explored the transcriptional consequences of combinatorial CNVs at single-cell resolution. We found single CNV lesions had distinct transcriptional identities: del5q-cells activated E2F/G2M checkpoint in HSC and erythroid cells (FDR<0.001), driven by E2F4 activity. Tri8 cells showed an expected increase in MYC and E2F targets (FDR<0.001) that was most enriched in erythroid cells, while increased inflammation was specifically found in GMP/HSCs (TNF/NF-κB, FDR<0.001). These results demonstrate that the same chromosomal gain produces fundamentally different biology depending on cellular context.

 In exploratory analysis, we assessed synergy between compound CNVs. In del5q:tri8-cells, 13 pathways showed synergistic activation that was not present with single lesions, while del5q antagonized the tri8 inflammatory signatures. This interaction was most pronounced in erythroid cells, where compound clones showed the highest primitive TF activity (TAL1) and suppression of differentiation-associated TFs (GATA1). These data indicate the most profound differentiation block occurs in erythroid cells (p<0.001).

 In summary, we present the largest single-cell transcriptomic study of TP53-MT AML. Our findings demonstrate that recurrent CNVs define distinct leukemia cell states. These findings identify chromosomal lesions as major contributors to the biological heterogeneity of TP53-MT AML and provide a framework for CNV-specific therapeutic stratification. Analyses on additional CNVs (del7, del17), cell types (neutrophil, monocyte) and genotypes (NRAS, FLT3) are ongoing, including in an expanded cohort (n=55).

Varsha Singh, PhD: No relevant conflicts of interest to declare.